Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
NCT02225665
Completed
The purpose of this study is to evaluate the safety and tolerability of repeat doses of T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning. CCR5 is a major co-receptor for HIV entry into T-cells. Disruption of CCR5 by zinc finger nuclease (SB-728mR), blocks HIV entry into the T-cells, therefore, protects the T-cells from HIV infection. Safety (primary outcome) and anti-viral effect (secondary outcome) of zinc finger nuclease-mediated CCR5 disrupted autologous T-cells (SB-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2021
Locations: Not set, San Francisco, California
Conditions: Human Immunodeficiency Virus (HIV)
Register for Updates
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
NCT02243371
Completed
The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2021
Locations: University of California, San Francisco, San Francisco, California +1 locations
Conditions: Previously Treated Metastatic Adenocarcinoma of the Pancreas
Register for Updates
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
NCT00002611
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney canc... Read More
Gender:
ALL
Ages:
Between 0 years and 15 years
Trial Updated:
02/23/2021
Locations: Southern California Permanente Medical Group, Downey, California +21 locations
Conditions: Kidney Cancer
Register for Updates
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
NCT00439296
Terminated
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemot... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/22/2021
Locations: Childrens Hospital Los Angeles, Los Angeles, California +2 locations
Conditions: Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
Register for Updates
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT01554371
Completed
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/14/2021
Locations: University of California, San Francisco, San Francisco, California
Conditions: Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, Neuropathy
Register for Updates
Rituximab and Belimumab for Lupus Nephritis
NCT02260934
Completed
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2020
Locations: UCLA Medical Center: Division of Rheumatology, Los Angeles, California +1 locations
Conditions: Lupus Nephritis
Register for Updates
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
NCT01675765
Completed
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: University of California at San Francisco, San Francisco, California
Conditions: Malignant Pleural Mesothelioma
Register for Updates
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
NCT01516307
Completed
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
09/14/2020
Locations: St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center, Fullerton, California +6 locations
Conditions: Metastatic Breast Cancer
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Central Hematology/Oncology Medical Group, Inc., Alhambra, California +47 locations
Conditions: Breast Cancer
Register for Updates
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
NCT00981799
Terminated
Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
09/08/2020
Locations: Childrens Hospital Los Angeles, Los Angeles, California +2 locations
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Register for Updates
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970
Completed
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is human epidermal growth factor receptor 2 (HER2)-positive and has spread to the lymph nodes or high-risk and has not spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2020
Locations: Community Cancer Institute, Clovis, California +15 locations
Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Register for Updates
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
NCT00390156
Completed
RATIONALE: Imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2020
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Unspecified Adult Solid Tumor
Register for Updates